Authors
Latest:
Genetic Risk Score Revolutionizes TNBC Prediction in Black WomenHolly Pederson, MD, and Elisha Hughes, PhD, discuss the findings and implications of a study evaluating risk of triple-negative breast cancer for Black women presented at the 2024 ASCO Annual Meeting.
Latest:
Can ChatGPT Prove Its Effectiveness in Health Care?A study by UVA Health found that while ChatGPT Plus holds potential for enhancing diagnoses, physicians need better training to use AI effectively.
Latest:
FDA OKs TLX007-CDx in Prostate Cancer TreatmentTLX007-CDx is now an FDA-approved PSMA PET imaging agent in prostate cancer.
Latest:
Exploring PSMA Therapies in Prostate CancerDeclan Murphy, MD, discusses the current interest in using PSMA, following the FDA’s approval of Gallium 68 PSMA-11, which marks the first ever drug for PET imaging of PSMA-positive lesions in men with prostate cancer.
Latest:
Navigating TKI Toxicities: Expert Perspectives and Clinical DistinctionsAn expert discusses how medical professionals counsel patients on adverse event (AE) risks with tyrosine kinase inhibitors (TKIs) such as lenvatinib/everolimus by highlighting key safety distinctions, including hypertension (HTN), fatigue, and diarrhea. For third-line tivozanib, tolerability and common toxicities (eg, Palmar-Plantar Erythrodysesthesia (PPE), HTN) are considered. AE incidence, discontinuation rates, and drug interactions guide treatment choices. Managing toxicities involves prevention, monitoring, and mitigation strategies, with dose modifications tailored based on severity and combination regimens. Community oncologists are advised on proactive AE management to optimize outcomes.
Latest:
Uncovering the Mechanism of Secondary Malignancies Post-CAR TRahul Banerjee, MD, FACP, physician-researcher at Fred Hutch Cancer Center in Seattle, WA, discusses the potential links between CAR T-cell therapy and secondary T-cell malignancies.
Latest:
AI Mortality Model Predicts End of Life, Boosts Palliative CareFinly Zachariah, MD, discusses the rationale behind implementing an AI mortality model at City of Hope, Duarte, California, which enhances the opportunity for patient-clinician discussions on end-of-life preferences, thereby boosting palliative care.
Latest:
Gene Editing Used to Enhance AML Antigen Targeting for CAR T-Cell TherapySiddhartha Mukherjee, MD, discusses potential means of targeting chimeric antigen receptor T-cell therapy for patients with acute myeloid leukemia.
Latest:
Lenvatinib Plus Pembrolizumab Shows Activity in Kidney CancerLenvatinib plus pembrolizumab showed activity and a favorable safety profile in nonmetastatic clear cell renal cell carcinoma, per phase 2 study results.
Latest:
Overview of MET Amplification and MET Exon 14 Skipping Mutations in NSCLCGiuseppe Giaccone, MD, PhD, discusses alterations in the MET gene that can be oncogenic drivers in patients with non–small cell lung cancer.
Latest:
High-Grade Toxicity Rates Influence Choice of IO in MelanomaDuring a live event, James W. Smithy, MD, MHS, and other oncologists discussed the tolerability of different immune checkpoint inhibitor regimens in melanoma including alternate dosing strategies.
Latest:
Future Outlooks for CAR T in Early R/R Multiple MyelomaPanelists discuss how chimeric antigen receptor (CAR) T-cell therapy could potentially be moved to earlier lines of treatment in relapsed/refractory multiple myeloma based on emerging trial data, improving outcomes through earlier intervention before patients develop treatment resistance.
Latest:
Defining Advances in the WHO Classification for AMLThe required blast threshold of 20% has now been omitted from AML with defining genetic abnormalities with the exception of AML with BCR::ABL1 and AML with CEBPA mutation.
Latest:
Darolutamide Plus ADT, Docetaxel Improves OS in Patients with mHSPC, Regardless of Disease Volume and RiskThe triplet therapy should become the new standard of care for this patient population, according to recent data.
Latest:
How Will New Immunotherapies Fit Into the Treatment Landscape of Follicular Lymphoma?Future directions for follicular lymphoma treatments include potential use earlier in treatment or as combination therapy, identifying patients who will benefit most from treatment, and minimizing the costs of therapy while maximizing accessibility.
Latest:
Current and Emergent Therapies for Systemic MastocytosisThe field of mastocytosis is witnessing a paradigm shift with precision medicine in the form of mutant KIT inhibitors.
Latest:
CAR T-Cell Use Generates Hope in Solid TumorsSteven M. Albelda, MD, discusses what he expects the future of chimeric antigen receptor T-cell use in solid tumors to look like.
Latest:
Treatments Differ in Rare Versus More Common Kidney CancersPavlos Msaouel, MD, PhD, discusses how the treatments and outcomes differ between patients with the rarer disease of renal medullary carcinoma than the more common renal cell carcinoma.
Latest:
Incorporating Biomarker Testing in Community Cancer Clinics: A Real-World Pilot StudyAlthough there is tremendous excitement about boundaries of science stretching beyond human imagination, realizing the real-world impact of scientific advancement on the health outcomes of patients provides a reality check on how far we still must go.
Latest:
Exploring Underrepresentation in Clinical Trials of Prostate CancerSmruthy Sivakumar, PhD, discusses a large-scale analysis of comprehensive genomic profiling utilization and ancestral characterization of the genomic landscape in patients with advanced prostate cancer.
Latest:
Exploring Immunotherapy and Radiation Therapy in Cervical CancerDomenica Lorusso, MD, PhD, discusses the rationale behind the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study.
Latest:
Emerging Options For Patients With Blood Cancers in Need of HSCTMitchell E. Horwitz, MD, discusses the next steps for research following the FDA approval of omidubicel.
Latest:
LaPelusa’s Journey in the Dynamic Field of GI OncologyIn this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.
Latest:
Eggener Urges Pragmatic Approach to Prostate Cancer InnovationsScott Eggener, MD, gave a talk at the LUGPA annual meeting titled “Leveraging Cutting-Edge Technologies to Enhance Prostate Cancer Treatments.”
Latest:
Dandapani Explores Radium-223 Combination in Metastatic Prostate CancerSavita Dandapani, MD, PhD, discusses the rationale behind a study evaluating the combination of radium-223, hormone therapy, and SBRT in metastatic castration-sensitive prostate cancer.
Latest:
Trastuzumab Deruxtecan Demonstrates Efficacy for mCRC in DESTINY-CRC01Salvatore Siena, MD, discusses the efficacy of the phase 2 DESTINY-CRC01 trial of trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer who have progressed on 2 or more treatments in this setting.
Latest:
Favorable Safety Profile Seen With Sabizabulin in mCRPCMark Markowski, MD, PhD, discusses the results of a phase 1b/2 study examining treatment with sabizabulin in patients with metastatic castration-resistant prostate cancer.
Latest:
Shifting the Paradigm: Challenges, Opportunities and Methodologies in Studying Rare CancersThe study of rare cancers has undergone a paradigm shift, transitioning from a singular disease entity approach to a more nuanced understanding of biomarker-defined subtypes.
Latest:
Breaking Down the Barriers to Effective T-Cell Lymphoma TreatmentStefan Barta, MD, discusses the heterogeneity of T-cell lymphoma, highlighting that a one-size-fits-all approach is ineffective and emphasizing the need for tailored treatment approaches.
